Vaccines & Biodefense

In the U.S., the recommended immunization series prevents approximately 33,000 deaths each year. Advancements in biotechnology have made it possible to produce vaccines that cannot transmit a virus or bacterium. This method has helped create more than 20 new vaccines against infectious agents, improved existing vaccines, and increased the amount of vaccine that can be produced.

Coronavirus
Biotech Response to COVID-19

As the threat of the novel coronavirus continues to grow globally, innovative biopharmaceutical companies are ramping up efforts to study the virus and develop vaccines and cures to protect individuals from contracting the virus.

Blog Posts
I am BIO episode 57
May 11, 2021
COVID-19 has brought to light many failures in our healthcare system – including the long-running issue of the lack of diversity in clinical trials. To understand how therapeutics or vaccines may affect a large…
Nurse
May 6, 2021
Today marks the start of National Nurses’ Week. Through May 12, we will celebrate nurses around the US – and worldwide - for the work they do for others and their significant contributions to our health care system. …
Vaccine
April 12, 2021
The “I AM BIO” podcast returns with an important topic – how to address COVID-19 vaccine hesitancy. Full episode here: https://www.bio.org/podcast or on your favorite podcast platform including …
Press Releases
April 20, 2021
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), yesterday sent a letter to U.S. Trade Representative (USTR) Ambassador Katherine Tai sharing BIO perspectives regarding the proposed WTO “TRIPS waiver” for COVID related products. The letter, written…
March 18, 2021
The Biotechnology Innovation Organization (BIO) welcomes the confirmations this week of Katherine Tai to the position of U.S. Trade Representative (USTR) and Xavier Becerra to lead the Department of Health and Human Services (HHS).  The United States leads the world in biotechnology…
March 10, 2021
Today, Congress passed the “American Rescue Plan” – a $1.9 trillion coronavirus relief package aimed at alleviating some of the economic and health impacts of the COVID-19 pandemic. Upon passage of the bill, Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation…
Letters, Comments & Testimony
April 6, 2021
On Tuesday, April 6th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s January 2021 draft industry guidance on “Human Gene Therapy for Neurodegenerative Diseases.” In its comments, BIO stated that while the guidance covers many critical development issues for gene therapies,…
March 26, 2021
On Friday, March 26th, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s public meeting announcement titled, “Best Practices for Development and Application of Disease Progression Models.” BIO appreciates that FDA is seeking input from stakeholders on three key areas,…
December 23, 2020
On Wednesday, December 23rd, BIO submitted comments on the U.S. Food and Drug Administration (FDA)’s October 2020 public workshop titled, “New Drugs Regulatory Program Modernization: Implementation of the Integrated Assessment of Marketing Applications and Integrated Review Documentation.” In its…
Patient-Take-Action
Become an Advocate for Biotechnology

Sign-up to join BIOAction, BIO's grassroots advocacy program. You will be notified about relevant policy issues where we need you to contact your lawmaker.